HN30 Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EDT
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)588.00
Market Cap
€3.21M
Enterprise Value€2.50M
Total Cash (Recent Filing)€1.19M
Total Debt (Recent Filing)€354.09K
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding61,077,354
10 Day Avg. Volume0
30 Day Avg. Volume588
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet StabilizationEquity turning positive in 2025 materially reduces short-term insolvency risk versus prior years. This stabilization improves creditor confidence and modestly expands financing options, supporting the company's runway and strategic choices over the next several months.
Modest Leverage In 2025Low debt relative to equity in 2025 limits interest burden and financial inflexibility, lowering fixed financial obligations. That structural leverage profile makes it easier to allocate limited cash to core development activities and raises the odds of surviving near-term funding cycles.
Improving Cash-burn TrendOperating and free cash outflows have narrowed versus trough years, indicating operational progress or cost control. While still negative, an improving burn trend reduces immediate capital needs and increases probability of reaching self-sufficiency or securing bridge financing within months.
Bears Say
No Recurring RevenueA complete absence of recurring revenue from 2021–2025 means the company lacks any operating cash generation base. This structural absence forces permanent reliance on external capital for operations, hindering sustainable growth and making multi-quarter resilience contingent on financing.
Persistent Operating LossesConsistent negative EBIT and EBITDA across reported years indicate core economics are not yet viable. Structural operating losses erode equity and require continual funding, constraining investments into R&D or commercialization and raising execution risk over the medium term.
Ongoing Negative Cash FlowNegative operating and free cash flow across all years shows persistent cash burn. Even with improved magnitude, the company remains dependent on external financing, which can lead to dilution or disrupted projects if capital markets tighten or financing terms worsen within the coming months.
Restart Life Sciences News
HN30 FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was €0.03 and its highest was €0.08 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is €3.21M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Aug 21, 2026 which is in 11 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 61,077,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in DE:HN30
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.